Publications by authors named "Edward Favours"

Claim this Profile
E
Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium.
Raushan T Kurmasheva, Abhik Bandyopadhyay, Edward Favours, Vanessa Del Pozo, Samson Ghilu

Pediatr Blood Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.
Raushan T Kurmasheva, Abhik Bandyopadhyay, Edward Favours, Vanessa Del Pozo, Samson Ghilu

Pediatr Blood Cancer· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.
Abhik Bandyopadhyay, Edward Favours, Doris A Phelps, Vanessa Del Pozo, Samson Ghilu

Pediatr Blood Cancer· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
Raushan T Kurmasheva, Melissa Sammons, Edward Favours, Jianwrong Wu, Dias Kurmashev

Pediatr Blood Cancer· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program.
Peter J Houghton, Christopher L Morton, Min Kang, C Patrick Reynolds, Catherine A Billups, Edward Favours

Pediatr Blood Cancer· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pediatric preclinical testing program: description of models and early testing results.
Peter J Houghton, Christopher L Morton, Chandra Tucker, Debbie Payne, Edward Favours

Pediatr Blood Cancer· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of ABT-751 against childhood cancer models in vivo.
Christopher L Morton, Edward G Favours, Kimberly S Mercer, Claire R Boltz, Jeri Carol Crumpton

Invest New Drugs· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Claire Graham, Chandra Tucker, Jeremy Creech, Edward Favours, Catherine A Billups

Clin Cancer Res· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Jennifer K Peterson, Chandra Tucker, Edward Favours, Pamela J Cheshire, Jeremy Creech

Clin Cancer Res· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis